U.S. government has invested $6 billion in Moderna’s Covid-19 vaccine while Avalon GloboCare works toward a complimentary intranasal vaccine

Keep your eye on is Avalon GloboCare (NASDAQ:AVCO)

52
Google Ads

According to “ U.S. government has invested $6 billion in Moderna’s Covid-19 Vaccine”  The federal government has now invested about $6 billion in the Covid-19 vaccine from Moderna NASDAQ: MRNA, the Cambridge, Mass., biotech that few outside the scientific and investment worlds had heard of a couple of years ago. Moderna said in a filing with the Securities and Exchange Commission on Wednesday that under a change in its government contract on April 18, it will receive as much as $236 million in additional reimbursement for costs associated with its late-stage vaccine trial on about 30,000 volunteers, including safety monitoring. The additional money is on top of the $5.75 billion that the government already poured into Moderna to help it develop, test, and manufacture the messenger RNA vaccine ― as well as to secure 300 million doses. 

In 2016, Moderna received $8 million with the potential for up to $125 million from the Biomedical Advanced Research and Development Authority, a component of the U.S. Department of Health and Human Services, to accelerate development of an mRNA vaccine for Zika. (The company is still working on that project.)What makes the bankrolling of Moderna’s Covid-19 vaccine so extraordinary, Foroohar said, was the scale, which “reflects how unusual the pandemic is and the fact that this is very literally a once-in-a-lifetime event.”

Moderna’s Covid-19 vaccine was the second one cleared in December by the Food and Drug Administration for emergency use. A week before, the FDA did the same for another mRNA vaccine, made by New York-based Pfizer and its German partner, BioNTech NASDAQ:BNTX .Pfizer  NYSE: PFE also has received $6 billion from the federal government, which has purchased 300 million doses for use in the U.S. The difference is that Pfizer didn’t accept federal funding to help develop, test, and manufacture the vaccine. Pfizer’s chief executive, Albert Bourla, said he didn’t want any government interference. His company signed an advance-purchase agreement, meaning it would not get paid until it delivered the vaccine doses. 

As big pharma and the U.S government invest billions to save lives, there is a smaller less known “sleeping giant” in the CAR-T space developing advanced S-layer technology with limitless applications in the key development of an intranasal vaccine.  S-Layer  “surface layer” technology is used to develop an intranasal vaccine that attaches to the mucosal membrane CEO Dr. David Jin pointed out. “We see our vaccine candidate as a complement to any injectable vaccines in clinical trials, because it could provide first-line immune protection at the virus’s entrance site”. Adding a coat of an S-layer onto solid surfaces can greatly improve the function of a therapeutic, vaccine, or device. The S-layer allows enhanced efficiency and interaction of targeted proteins and molecules for better function.

Avalon GloboCare is in the process of establishing a state-of-the-art research facility, the Christian Doppler Laboratory, located on the BOKU campus in Vienna, Austria, under the scientific leadership of Professor Eva-Kathrin Ehmoser, the Head of BOKU’s Institute for Synthetic Bioarchitectures and Professor Uwe Sleytr, a member of the Austrian Academy of Sciences. In connection with the new facility, Avalon and BOKU have signed a Memorandum of Understanding (MOU) to jointly apply for a matching research grant from the prestigious Christian Doppler Laboratory Foundation. Avalon also has research being done in MIT (Massachusetts Institute of Technology), the UNRLS (University of Natural Resources and life sciences in Australia), Weill Cornell Medicine in New York City and the Lu Daopei Medical Group in China, which has the country’s top ranked hematology and bone marrow transplant program 

In the December 2020 issue of Nature’s Biopharma Dealmakers, Avalon’s President and CEO, David Jin, M.D., Ph.D., highlighted Avalon’s ongoing scientific and clinical developments including a first-in-human trial of a mucosal, intranasal vaccine against SARS-CoV-2 that is planned for early 2021. Dr. Jin also described the company’s innovative, allogeneic mesenchymal stromal cell (MSC) therapy candidate, CB-MSC-1, which possess unique anti-inflammatory and immunomodulatory activities, as well as AVA-001, Avalon’s third-generation CAR T cell therapy that has shown robust activity in patients with relapsed, refractory B cell acute lymphoblastic leukemia in a Phase 1 trial (Avalon feature in Biopharma Dealmakers).

“We are excited and motivated to join forces with the researchers at BOKU to drive innovation. We have already begun a collaboration on the mucosal SARS-CoV-2 vaccine and are moving quickly to establish additional joint research endeavors to bring about innovative technologies and new medicines to patients,” said Dr. Jin.

Google Ads

Avalon GloboCare, is a young, $100 million market cap company that has arguably some of the brightest minds in cell-based technology who have a competitive advantage with their “S-Layer” technology in a vaccine market that is expected to grow to approximately 93.billion by 2026 according to Forbes business . This small cap biotechnology company is working towards the goal of changing the way we fight the devastating effects of diseases that relentlessly attack our immune systems by using our own bodies against us. In the first quarter of 2020, Avalon GloboCare successfully completed a phase 1 first-in-human clinical study of AVA-001 in China for the treatment of relapsed refractory B cell acute lymphoblastic leukemia (R/R B-ALL). 90% of R/R B-ALL patients achieved complete remission with one dose and within one month of treatment, and then proceeded to a curative-intent allogeneic bone marrow transplant.  With more upcoming catalysts in early 2021, it is safe to say that there is a large potential upside in AVCO’s stock is currently trading at its 52 week know at 1.00 in change , as the market is anticipating updates on their progress on multiple clinical trials, leaving the question most investors are asking themselves.” When will Avalon GloboCare (NASDAQ:AVCO) take off ?” 

About EmergingGrowth.com

All information contained herein as well as on the EmergingGrowth.com website is obtained from sources believed to be reliable but not guaranteed to be accurate or all-inclusive. All material contained within this article was provided to EmergingGrowth.com by a third party, is for informational purposes only, is not the opinion of EmergingGrowth.com and should not be construed as an offer or solicitation to buy or sell securities. The information includes certain forward-looking statements, which may be affected by unforeseen circumstances and / or certain risks.  This report is not without bias. EmergingGrowth.com has motivation by means of either self-marketing or EmergingGrowth.com has been compensated by or for a company or companies discussed in this article. EmergingGrowth.com is compensated two thousand five hundred dollars per month beginning January 11, 2021 in consideration for its work with Avalon GloboCare Corp. EmergingGrowth.com may receive additional compensation, and may have received past compensation by or for this same company details about which can be found in our full disclosure, here, https://emerginggrowth.com/6282-723726/. You can easily lose money investing in highly speculative small cap stocks like the ones mentioned within. Please consult an investment professional before investing in anything viewed within. When EmergingGrowth.com is long shares it will sell those shares. In addition, please make sure you read and understand the Terms of Use, Privacy Policy and the Disclosure posted on the EmergingGrowth.com website.